Skip to main content
    O

    Oramed Pharmaceuticals Inc (ORMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.87
    -0.03 (-0.77%)

    Market Cap: $169.59M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Oramed Pharmaceuticals Inc (ORMP) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Oramed Pharmaceuticals (ORMP) trades at 4.2x trailing earnings. Its P/B of 0.5x is below its 5-year median of 0.7x. Its forward P/E is 0.8x.

    Current Multiples

    Its forward P/E on consensus earnings for the next fiscal year to be reported is below its trailing P/E. Consensus earnings per share are about 425.0% higher than over the last four quarters.

    MultipleValue
    P/E (trailing)4.2x
    Forward P/E0.8x
    Price to book0.5x
    PEGN/A
    FCF yield-2.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 77.3% below 2.2x.

    MultipleCurrent5-year median10-year median
    P/SN/AN/A48.8x
    P/B0.5x0.7x2.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 103 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 19.0x in 2018 to 173.2x in 2022.

    Year endPriceP/EP/SP/B
    2025$2.851.9x58.8x0.6x
    2024$2.42N/AN/A0.7x
    2023$2.3116.5x69.2x0.6x
    2022$12.03N/A173.2x3.1x
    2021$14.28N/A161.2x3.1x
    2020$4.24N/A33.5x3.6x
    2019$5.15N/A33.3x5.2x
    2018$3.00N/A19.0x1.8x
    2017$9.00N/A50.4x5.6x
    2016$6.12N/A64.3x3.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About ORMP

    What is ORMP's forward P/E ratio?

    Oramed Pharmaceuticals has a forward P/E ratio of 0.8x.